Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (314)	9/10/1999 1:56:00 PM
From: biowa	Respond to of 666

David, <<this won't make the FDA any easier on anyone>> Exactly. That was my thought as I read the WSJ version. There are already program areas where the FDA is in a virtual state of paralysis because of some misstep - even in clinical trials - that the press jumps on. Good example is red cell substitutes where Baxter's poor PIII design (and consequent failure) has kept the FDA from even deciding what efficacy and safety criteria it will accept; and there are folk currently in pivotal trials! So, just what we need: more FDA staff covering their backsides because they might be answering to G-men. How about homicide investigations for delaying life saving medications? There, I feel better... biowa